Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | WNT1 | P04628 | 7/20 | 0.43 |
| ▸ | GSK3B | P49841 | 7/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.43 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336323 | 0.91 | GRM2 (0.44) | GRM2WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL13362817 | 0.89 | MAP4K1 (0.44) | GRM2WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL13336322 | 0.88 | GRM2 (0.42) | GRM2WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL13362896 | 0.88 | MAP4K1 (0.43) | WNT1GSK3BDYRK1AMAP4K1MAP4K3 | |
| SCHEMBL13362797 | 0.81 | TTK (0.44) | GRM2WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL13251910 | 0.80 | MAP4K1 (0.43) | DYRK1AMAP4K1MAP4K3DDR2TTK | |
| SCHEMBL13336180 | 0.79 | MAP4K1 (0.44) | GRM2WNT1GSK3BDYRK1AMAP4K1 | |
| SCHEMBL13573976 | 0.79 | MAP4K1 (0.44) | WNT1GSK3BDYRK1AMAP4K1MAP4K3 | |
| SCHEMBL13573972 | 0.78 | MAP4K1 (0.44) | WNT1GSK3BDYRK1AMAP4K1MAP4K3 | |
| SCHEMBL13336028 | 0.77 | MAP4K1 (0.43) | WNT1GSK3BDYRK1AMAP4K1MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | GRM2 2795/4885WNT1 759/4885GSK3B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.